This is a pilot randomized controlled trial in individuals with probable Alzheimer's disease
testing the effects of 10 mg dapagliflozin, taken daily for 12 weeks, on cerebral n-acetyl
aspartate (NAA) levels using magnetic resonance spectroscopy (MRS). The investigators will
also examine the safety and tolerability of dapagliflozin and explore the effects on systemic
NAA levels in blood and urine, cerebral metabolism (fluorodeoxyglucose [FDG] PET), systemic
metabolic biomarkers that indicate and quantify secondary metabolic effects, and cognitive
performance.